1. [CASE 1 — QUESTION 1] A 44-year-old woman presents to her hematologist with a 6-month history of fatigue, dark morning urine, and one episode of severe abdominal pain requiring emergency evaluation. Laboratory workup reveals: hemoglobin 7.8 g/dL (low), reticulocyte count elevated, LDH 890 U/L (markedly elevated), haptoglobin undetectable, total bilirubin 2.8 mg/dL, negative direct antiglobulin test (DAT — Coombs test), and a platelet count of 88,000/mcL. Urinalysis shows hemosiderinuria. Peripheral blood smear shows no fragmented red cells (schistocytes). The hematologist suspects paroxysmal nocturnal hemoglobinuria (PNH). Which test will confirm the diagnosis, and what specific cellular defect will it identify?

• A) Bone marrow biopsy with cytogenetics; PNH is a clonal stem cell disorder confirmed by identifying a specific chromosomal translocation — t(X;Y)(p22;q11) — in myeloid progenitors; the translocation disrupts the PIGA locus and impairs GPI anchor synthesis in affected clones.
• B) Serum complement C3 and C4 levels combined with anti-factor H antibody titer; PNH is a complement-mediated hemolytic disorder confirmed by demonstrating low C3, low C4, and circulating anti-factor H antibodies that destabilize the alternative pathway C3 convertase on erythrocyte surfaces.
• C) Flow cytometry of peripheral blood erythrocytes and granulocytes for GPI-anchored proteins (CD55 and CD59 on erythrocytes; CD14 and CD24 on granulocytes); a discrete population of cells lacking these GPI-anchored surface proteins confirms the somatic PIGA (phosphatidylinositol glycan class A) gene mutation that prevents GPI anchor biosynthesis, leaving affected blood cells without the complement regulatory proteins that protect host cells from spontaneous MAC-mediated lysis.
• D) Sucrose hemolysis test (sucrose lysis test) combined with serum protein electrophoresis; the sucrose test identifies complement-sensitive erythrocytes through osmotic lysis in low-ionic-strength sucrose solution, and serum electrophoresis identifies the monoclonal immunoglobulin that sensitizes PNH erythrocytes to complement attack.
• E) Peripheral blood karyotype and JAK2 V617F mutation analysis; PNH is a myeloproliferative neoplasm confirmed by identifying the JAK2 V617F gain-of-function mutation in hematopoietic stem cells, which simultaneously activates complement through constitutive STAT5 signaling and produces the characteristic hemolytic anemia and thrombocytopenia.

2. [CASE 1 — QUESTION 2] Continuing with the same patient. Flow cytometry confirms a large PNH clone (78% of granulocytes GPI-deficient). Her history also reveals the prior abdominal pain episode was a hepatic vein thrombosis (Budd-Chiari syndrome), now treated with anticoagulation. The hematologist plans to start eculizumab. Before the first infusion can be given, which combination of pre-treatment requirements must be completed, and what is the minimum timing requirement?

• A) Both MenACWY (quadrivalent meningococcal conjugate vaccine, covering serogroups A, C, W, and Y) and a meningococcal serogroup B vaccine (MenB — such as MenB-FHbp or MenB-4C) must be administered at least two weeks before the first eculizumab dose to allow time for protective antibody development; many centers also initiate prophylactic oral penicillin (or amoxicillin) indefinitely throughout eculizumab therapy because terminal complement blockade eliminates the primary bactericidal defense against encapsulated organisms, particularly Neisseria meningitidis; the anticoagulation for Budd-Chiari syndrome should be continued alongside eculizumab, not discontinued.
• B) Only MenACWY vaccination is required before eculizumab; MenB vaccination is optional and not included in the FDA-labeled indication; the MenB vaccine was approved after eculizumab and is a guideline recommendation only in selected high-risk geographic areas; anticoagulation should be discontinued once eculizumab is started because eculizumab eliminates the complement-mediated platelet activation that was the proximate cause of the thrombosis.
• C) Latent tuberculosis screening (IGRA or TST) and hepatitis B serology are the mandatory pre-treatment requirements before eculizumab; meningococcal vaccination is optional because the infection risk with eculizumab primarily involves opportunistic organisms controlled by T-cell immunity rather than by the terminal complement pathway; anticoagulation should be continued independently of eculizumab initiation.
• D) Pre-treatment complete blood count, liver function tests, and renal function panel are the only required pre-eculizumab tests; eculizumab has no specific infection risk beyond that seen with other immunosuppressive biologics, and the FDA label requires only standard safety laboratory evaluation before the first dose; meningococcal vaccination is not a labeled requirement.
• E) MenACWY vaccination must be given at least 6 weeks before eculizumab, and the patient must also complete a 2-week course of prophylactic ciprofloxacin to eradicate any nasopharyngeal meningococcal carriage before starting therapy; MenB vaccination is contraindicated in patients with complement pathway activation disorders because the live attenuated component of MenB vaccines can cause disseminated meningococcal disease in complement-deficient hosts.

3. [CASE 1 — QUESTION 3] Continuing with the same patient. She has now been on eculizumab for 18 months. Her LDH has normalized and hemoglobinuria resolved. However, she remains persistently anemic with hemoglobin 8.9 g/dL and an elevated reticulocyte count. Repeat flow cytometry confirms the PNH clone remains large. Peripheral blood smear shows no fragmented cells, and a direct antiglobulin test is now weakly positive for C3d (complement fragment deposition). Her hematologist explains that she is experiencing extravascular hemolysis despite adequate intravascular hemolysis control. Which mechanism explains this phenomenon and what therapeutic modification addresses it?

• A) The residual anemia reflects eculizumab-induced bone marrow suppression; eculizumab's complement blockade prevents C3b-mediated stimulation of erythropoietin-sensitive bone marrow progenitors, reducing red cell production; treatment requires addition of recombinant erythropoietin to stimulate erythroid progenitor differentiation independently of complement.
• B) The C3d deposition indicates development of autoimmune hemolytic anemia (AIHA) as a complication of eculizumab therapy; eculizumab shifts the Th1/Th2 balance toward Th2, promoting IgG autoantibody production against erythrocyte antigens; treatment requires addition of rituximab to deplete the B cells producing anti-erythrocyte autoantibodies.
• C) The residual anemia is caused by eculizumab drug resistance from anti-drug antibody (ADA) formation; ADA neutralizes eculizumab, allowing resumption of C5 cleavage and intravascular hemolysis; treatment requires switching to ravulizumab, which has a modified Fc region that is less immunogenic and maintains complete C5 blockade without ADA interference.
• D) The C3d on erythrocytes results from eculizumab trough-period C5 breakthrough; in the 48–72 hours before each scheduled infusion, residual C5 activity allows MAC formation and sub-lytic complement attack that deposits C3 fragments; the solution is to switch to ravulizumab, whose every-8-week dosing eliminates trough periods and prevents this intermittent C3 deposition.
• E) Eculizumab blocks C5 downstream of C3, preventing MAC formation and controlling intravascular hemolysis, but does not block the upstream C3 activation that continues to deposit C3b on PNH erythrocyte surfaces; surface C3b and its downstream cleavage product C3d opsonize PNH erythrocytes for phagocytic recognition by complement receptors CR1 and CR3 on hepatic Kupffer cells and splenic macrophages, causing extravascular hemolysis that is independent of MAC; switching to or adding pegcetacoplan — a C3/C3b inhibitor acting upstream of C5 — blocks C3b deposition and eliminates both extravascular and intravascular hemolysis.

4. [CASE 1 — QUESTION 4] Continuing with the same patient. She has been switched to pegcetacoplan with excellent hemoglobin response (now 11.8 g/dL). She is now 31 years old (several years have passed) and is considering pregnancy. She asks her hematologist whether pegcetacoplan can be continued during pregnancy and what risks PNH poses in the obstetric setting. Which response most accurately addresses the pharmacological and clinical considerations for PNH management in pregnancy?

• A) Pegcetacoplan must be discontinued at conception because it crosses the placenta and inhibits fetal complement; fetal complement activity is essential for placental trophoblast invasion and spiral artery remodeling, and its inhibition causes early pregnancy loss and failed placentation; all complement inhibitors are absolutely contraindicated throughout pregnancy in PNH.
• B) Pregnancy in PNH is high risk because physiological complement activation is amplified during gestation — particularly during delivery and in the early postpartum period — creating heightened PNH flare risk; complement inhibitors including eculizumab and pegcetacoplan have been used successfully throughout pregnancy in PNH patients, and current expert guidance supports continuing complement inhibition during pregnancy with close monitoring by maternal-fetal medicine and hematology; dose adjustments or increased dosing frequency may be necessary as plasma volume expands; anticoagulation throughout pregnancy is strongly recommended given PNH's inherent thrombotic risk, which is amplified by pregnancy-associated hypercoagulability.
• C) Pegcetacoplan should be switched to eculizumab for the duration of pregnancy because pegcetacoplan's PEGylation prevents placental transfer and results in insufficient maternal complement inhibition during the high-risk peripartum period; eculizumab, which crosses the placenta via FcRn, provides the added benefit of neonatal complement inhibition that protects the infant from complement-mediated hemolysis in the immediate neonatal period.
• D) Pregnancy is absolutely contraindicated in all PNH patients because the combination of pregnancy-related complement amplification and anticoagulation requirement creates an unacceptable maternal mortality risk exceeding 30%; the patient should be counseled that complement inhibitors cannot adequately control PNH flares triggered by the hormonal changes of pregnancy, and that hematopoietic stem cell transplant (HSCT) should be completed before any attempt at conception.
• E) Pregnancy in PNH requires stopping all complement inhibitors and switching to daily prophylactic plasma exchange to remove circulating complement proteins; complement inhibitors are teratogenic in the first trimester and are associated with neural tube defects; plasma exchange safely removes complement without pharmacological fetal exposure and is the only evidence-based complement management strategy during PNH pregnancy.

5. [CASE 2 — QUESTION 1] A 38-year-old man with a 4-year history of seropositive rheumatoid arthritis (RF-positive and anti-CCP antibody-positive) has been on methotrexate 20 mg weekly for 18 months without adequate disease control. He has persistent synovitis in multiple joints, elevated CRP of 18 mg/L, and an mTSS (modified total Sharp score) progression indicating ongoing radiographic joint damage. He has no prior infections, no TB exposure history, no HBV or HCV exposure, and no other medical comorbidities. His rheumatologist plans to add a biologic agent. Which biologic class is the appropriate first-line choice, and why?

• A) An IL-6 receptor inhibitor (tocilizumab or sarilumab) should be selected as the first biologic because IL-6 is the primary driver of the elevated CRP observed in this patient; targeting IL-6R will normalize CRP, providing an objective monitoring tool for disease activity; TNF inhibitors are reserved for patients who fail IL-6 inhibitors because tocilizumab has demonstrated superior CRP suppression in head-to-head trials.
• B) A JAK inhibitor (tofacitinib or upadacitinib) should be selected because oral administration avoids the injection-related compliance issues associated with subcutaneous biologics, and JAK inhibitors have demonstrated equivalent or superior efficacy to TNF inhibitors in RA trials; the black box warning for MACE, VTE, and malignancy does not apply to patients under age 50 with no cardiovascular risk factors.
• C) An IL-17A inhibitor (secukinumab or ixekizumab) should be selected because IL-17A is the dominant cytokine driving synovial inflammation and joint destruction in seropositive RA with anti-CCP antibodies; anti-CCP-positive RA has a predominantly Th17 phenotype that responds preferentially to IL-17A blockade compared to TNF-alpha inhibition.
• D) A TNF-alpha inhibitor added to methotrexate is the recommended first-line biologic for RA patients with inadequate response to conventional DMARDs (disease-modifying antirheumatic drugs); multiple guidelines including ACR and EULAR recommend TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab) as first-choice biologics in this setting, with the combination of TNF inhibitor plus methotrexate providing superior efficacy and reduced immunogenicity compared to biologic monotherapy; before initiating any TNF inhibitor, latent TB screening (IGRA or TST) and HBV serology are mandatory.
• E) A B-cell depleting agent (rituximab — anti-CD20 monoclonal antibody) should be selected as the preferred first biologic in seropositive anti-CCP-positive RA because anti-CCP antibodies are produced by CD20-positive B cells; rituximab directly eliminates the autoantibody-producing B-cell clones responsible for disease pathogenesis and is therefore the mechanistically most targeted approach for this patient's antibody-mediated disease phenotype.

6. [CASE 2 — QUESTION 2] Continuing with the same patient. Pre-treatment screening returns: HBsAg negative, anti-HBc negative. However, his QuantiFERON-TB Gold Plus (IGRA — interferon-gamma release assay, a blood test that detects immune sensitization to Mycobacterium tuberculosis antigens) returns reactive (positive). Chest radiograph shows a small calcified granuloma in the right upper lobe but no active infiltrates. He has no prior history of TB treatment and no respiratory symptoms. Which management approach is most appropriate before initiating adalimumab?

• A) Adalimumab should be started immediately without any delay because the positive IGRA reflects remote exposure to environmental mycobacteria cross-reactive with M. tuberculosis antigens rather than true latent TB infection; a calcified granuloma on chest radiograph indicates the infection was cleared completely and poses no reactivation risk; prophylactic isoniazid is unnecessary and carries hepatotoxicity risk without benefit.
• B) Latent TB treatment with isoniazid (INH) 300 mg daily should be initiated immediately; most guidelines recommend starting the TNF inhibitor after at least 4 weeks of INH prophylaxis rather than waiting for the full 9-month course, provided active TB has been excluded; the combination of radiographic granuloma and positive IGRA confirms latent TB infection (LTBI), and TNF-alpha blockade carries a well-established risk of TB reactivation through disruption of granuloma structural integrity that depends on TNF-alpha-mediated macrophage activation and T-cell retention.
• C) The patient should receive a 6-month course of full anti-tuberculosis combination therapy (isoniazid, rifampin, pyrazinamide, and ethambutol) before adalimumab can be initiated; a calcified granuloma combined with a positive IGRA constitutes a diagnosis of prior active TB requiring full re-treatment rather than LTBI prophylaxis, and TNF inhibitors are permanently contraindicated in patients with any prior TB exposure.
• D) The IGRA result should be repeated once because a single positive IGRA is insufficient to confirm LTBI and may reflect a false positive from BCG vaccination; because BCG vaccination is common in many countries and produces IGRA positivity, the result should be considered indeterminate until confirmed by a second test; adalimumab can be started pending the repeat IGRA.
• E) The positive IGRA requires immediate initiation of bronchoscopy with bronchoalveolar lavage to exclude active pulmonary TB before any anti-tuberculosis or biologic therapy is started; active TB cannot be excluded by chest radiograph alone in immunocompromised patients, and a positive IGRA in this context requires microbiological confirmation of the absence of active disease.

7. [CASE 2 — QUESTION 3] Continuing with the same patient. He completed 9 months of isoniazid prophylaxis and adalimumab was started after 4 weeks of INH with good initial RA control. Eight months into adalimumab therapy, his disease flares with return of synovitis and elevated CRP. Drug level monitoring reveals a low adalimumab trough concentration of 2.1 mcg/mL (therapeutic target greater than 5–8 mcg/mL) and a high anti-adalimumab antibody (ADA) titer. Which explanation and management approach is most appropriate?

• A) The low drug level with high ADA titer confirms immunogenicity-driven secondary loss of efficacy; anti-adalimumab antibodies (ADA) neutralize the drug and accelerate its clearance, reducing trough concentrations below therapeutic levels; the most appropriate management is to optimize methotrexate dosing (methotrexate is the most effective immunomodulator for reducing ADA formation to adalimumab), and if ADA titers remain high despite methotrexate optimization, switching to a different TNF inhibitor (etanercept has lower immunogenicity due to its fusion protein structure) or a different biologic mechanism class (IL-6 inhibitor, JAK inhibitor) is appropriate.
• B) The low trough concentration indicates that adalimumab is being metabolized too rapidly due to CYP3A4 enzyme induction from the completed isoniazid course; isoniazid is a potent CYP3A4 inducer and its prior use permanently upregulated hepatic metabolism of adalimumab; the management is to increase adalimumab dose frequency from every 2 weeks to weekly to compensate for the enhanced clearance.
• C) The low adalimumab trough with high ADA confirms that this patient has developed a hypersensitivity reaction to adalimumab's murine-derived variable region sequences; adalimumab, as a fully human antibody, should not generate anti-drug antibodies in patients with intact immune systems; the ADA must represent cross-reactive antibodies originally generated against the calcified granuloma mycobacterial antigens that cross-react with adalimumab's CDR (complementarity-determining region) sequences.
• D) Low trough adalimumab with high ADA indicates that the patient's RA is now biologically driven by a non-TNF cytokine pathway that has emerged as TNF blockade has been maintained; the low drug level is pharmacodynamically irrelevant and the ADA represents a protective response against ongoing TNF inhibition; treatment should continue with adalimumab dose escalation to overwhelm the ADA, as high-dose biologic therapy can overcome the pathological pathway switch.
• E) The low adalimumab concentration with elevated ADA confirms complete renal drug elimination; anti-adalimumab antibodies form immune complexes with adalimumab that are filtered by the glomerulus and excreted renally; serum creatinine should be measured to confirm the degree of renal impairment causing excessive drug clearance, and dose adjustments should be based on creatinine clearance calculated using the Cockcroft-Gault equation.

8. [CASE 2 — QUESTION 4] Continuing with the same patient. He was switched to tocilizumab (anti-IL-6 receptor monoclonal antibody) after adalimumab failure, with good RA disease control over the next 14 months. He now presents with 4 days of fever, rigors, and purulent cough. His CRP returns at less than 0.5 mg/L (undetectable). The urgent care physician is reassured by the normal CRP and considers discharge with a 5-day course of oral azithromycin. Which pharmacological knowledge should change this management plan?

• A) The undetectable CRP confirms that this patient does not have a serious bacterial infection; tocilizumab's IL-6 receptor blockade abolishes CRP synthesis only in sterile inflammatory states such as RA flares; active bacterial infection generates IL-1 beta and TNF-alpha-driven CRP synthesis that bypasses IL-6 receptor blockade, meaning a negative CRP in a tocilizumab-treated patient is just as reassuring as in any other patient and is incompatible with significant bacterial pneumonia.
• B) The undetectable CRP reflects optimal tocilizumab pharmacodynamics and indicates that the drug is working correctly; CRP suppression below the assay's lower limit of detection confirms complete IL-6 receptor blockade and is the target therapeutic endpoint for tocilizumab therapy; this result should reassure the treating physician that the patient's immune system is optimally tuned to suppress inflammatory damage from the respiratory infection.
• C) The undetectable CRP indicates that this patient is receiving an excessive dose of tocilizumab that has completely abrogated his acute-phase response; the dose should be immediately reduced and restarted at half the standard dose, and the CRP measurement should be repeated after 48 hours; if CRP remains undetectable after dose reduction, the drug should be held until CRP rises above 5 mg/L, confirming that the patient's acute-phase capacity has been restored.
• D) The low CRP reflects successful suppression of the RA inflammatory background by tocilizumab; the physician is correct that a low CRP is reassuring in this context; however, the patient should be tested for Legionella and pneumococcal urinary antigens before discharge because tocilizumab's IL-6 blockade specifically impairs macrophage killing of atypical respiratory organisms through STAT3 suppression, and empirical azithromycin appropriately covers Legionella in this immunosuppressed patient.
• E) CRP cannot be used as an infection severity marker in patients on IL-6 receptor inhibitors; tocilizumab blocks IL-6 receptor signaling through gp130-JAK1/JAK2-STAT3 in hepatocytes, abolishing IL-6-driven CRP synthesis so completely that CRP remains undetectable even during life-threatening sepsis; this patient with fever, rigors, and purulent cough requires full infectious evaluation including chest imaging, blood cultures, sputum cultures, complete blood count with differential, and procalcitonin (PCT — an infection biomarker driven primarily by bacterial endotoxin and TNF-alpha/IL-1 rather than IL-6 and therefore more reliable in tocilizumab-treated patients), and should not be managed as an outpatient based on an uninterpretable CRP.

9. [CASE 3 — QUESTION 1] A 52-year-old woman with severe atopic dermatitis (eczema) affecting 35% of her body surface area has failed topical corticosteroids, tacrolimus ointment, and cyclosporine. She is referred to a dermatologist for biologic therapy. She also has a history of moderate persistent asthma that is incompletely controlled on inhaled corticosteroids plus a long-acting beta agonist. She has no other significant medical history. Her dermatologist selects dupilumab. Which mechanistic explanation best justifies why dupilumab is particularly well-suited for this patient's combination of conditions?

• A) Dupilumab is selected because it is the only biologic that specifically targets eosinophil survival through IL-5 receptor alpha (IL-5Ralpha) blockade; because eosinophils are elevated in both atopic dermatitis skin and asthmatic airways, dupilumab's eosinophil-depleting mechanism addresses the shared cellular mediator of both conditions simultaneously.
• B) Dupilumab blocks IL-4 receptor alpha (IL-4Ralpha), the shared subunit of both the type I IL-4 receptor (binding IL-4 alone on hematopoietic cells) and the type II IL-4 receptor (binding both IL-4 and IL-13 on non-hematopoietic tissues including skin keratinocytes and airway epithelium); this single antibody therefore simultaneously suppresses IL-4-driven Th2 differentiation and IgE class switching AND IL-13-driven skin barrier dysfunction, mucus hypersecretion, and airway hyperreactivity — addressing the shared type 2 inflammatory biology driving both atopic dermatitis and asthma.
• C) Dupilumab is selected because it blocks both the IL-4 and IL-13 cytokines directly as a bispecific antibody with separate antigen-binding domains for each cytokine; the bispecific format allows higher molar drug efficiency than receptor-level blockade because targeting two ligands with one molecule is pharmacoeconomically superior to targeting their shared receptor.
• D) Dupilumab is preferred in this patient because it is the only biologic approved for both atopic dermatitis and asthma in patients over age 50; biologics targeting IL-5 and IL-5Ralpha are only approved for patients under age 50 in the eosinophilic asthma indication, making dupilumab the only age-appropriate dual-indication option for this patient.
• E) Dupilumab is selected because it inhibits TSLP (thymic stromal lymphopoietin) — the upstream epithelial-derived cytokine that initiates both allergic skin and airway inflammation; by blocking TSLP before it can activate dendritic cells and ILC2s, dupilumab prevents the entire downstream type 2 cascade responsible for both conditions at its most proximal step.

10. [CASE 3 — QUESTION 2] Continuing with the same patient. Six weeks after starting dupilumab she returns reporting excellent skin improvement and reduced asthma exacerbations, but notes bilateral eye redness, a gritty sensation, and mucoid discharge that developed 3 weeks after her first injection. Slit-lamp examination reveals bilateral conjunctival injection and papillary changes without keratitis. She asks whether she must stop dupilumab because she is worried about losing the benefit to her skin and lungs. Which response is most accurate?

• A) Dupilumab must be immediately discontinued and the patient referred to an allergist for monoclonal antibody hypersensitivity evaluation; bilateral conjunctivitis developing 3 weeks after the first injection is consistent with a type III immune complex hypersensitivity reaction to dupilumab's human IgG4 framework regions, which must be confirmed by serum complement levels and anti-dupilumab antibody titer before any further biologic therapy is considered.
• B) This presentation is consistent with bacterial conjunctivitis caused by Staphylococcus aureus, which colonizes atopic dermatitis skin and can seed the conjunctivae; the appropriate management is a 7-day course of topical ofloxacin eye drops and continuation of dupilumab; the patient should be counseled to avoid touching her face and wash hands frequently to prevent recolonization.
• C) The conjunctivitis represents a paradoxical worsening of the ocular atopic disease because dupilumab shifts the systemic immune balance toward Th1; by suppressing IL-4 and IL-13 (which normally inhibit Th1 responses), dupilumab increases IFN-gamma production that drives a Th1-mediated conjunctivitis; dupilumab dose should be reduced to every-4-week injections to reduce the Th1-promoting effect while maintaining partial atopic disease control.
• D) Dupilumab-associated conjunctivitis is the most common adverse effect of dupilumab in atopic dermatitis, affecting approximately 10 to 25% of patients; it is related to altered IL-4 and IL-13 signaling in the conjunctival mucosa — potentially affecting goblet cell mucin production, Demodex mite colonization patterns, or local immune homeostasis — and is not a hypersensitivity reaction or a reason to discontinue dupilumab; appropriate management includes referral to ophthalmology, topical ophthalmic cyclosporine (Restasis) or tacrolimus eye drops, and preservative-free lubricating drops while continuing dupilumab.
• E) The conjunctivitis indicates that the dupilumab dose is too high and is causing global IL-4Ralpha blockade including in the tear film; reducing the dupilumab injection to once monthly rather than every 2 weeks will maintain adequate skin and lung benefit while restoring sufficient IL-4 signaling in the conjunctival mucosa to resolve the ocular inflammation; no topical ocular treatment is needed if the systemic dose is appropriately reduced.

11. [CASE 3 — QUESTION 3] Continuing with the same patient. She is now 3 years into dupilumab therapy with excellent control of both her atopic dermatitis and asthma. She is now 46 years old and discovers she is 7 weeks pregnant. She is concerned about continuing dupilumab and asks her dermatologist whether it poses a risk to the fetus. Which response most accurately reflects the current pharmacological understanding and clinical guidance?

• A) Dupilumab must be immediately discontinued at week 7 because IgG4 antibodies cross the placenta via FcRn at a higher rate than IgG1 antibodies during the first trimester; first-trimester dupilumab exposure carries a documented 12% rate of major congenital anomalies including cardiac septal defects and neural tube malformations based on post-marketing registry data, and the drug is FDA pregnancy category X.
• B) Dupilumab can be continued throughout pregnancy without any concern; as an IgG4 subclass antibody, dupilumab has virtually no placental transfer during any trimester because IgG4 has negligible FcRn binding affinity; fetal drug exposure is functionally zero regardless of gestational age at last dose, making dupilumab safer in pregnancy than any IgG1 biologic.
• C) Dupilumab is a human IgG4 monoclonal antibody that does cross the placenta via FcRn, though IgG4 has lower FcRn affinity than IgG1 and therefore crosses less efficiently; limited registry and post-marketing data have not identified an increased rate of major congenital anomalies or adverse pregnancy outcomes attributable to dupilumab; current guidance from major dermatology and allergy societies suggests that the decision to continue dupilumab during pregnancy should be individualized based on disease severity — given that uncontrolled severe atopic dermatitis and asthma carry their own maternal and fetal risks (preterm birth, low birth weight, maternal psychological stress), many experts support continuation when disease is severe and previously well-controlled on dupilumab; fetal and neonatal monitoring is recommended.
• D) Dupilumab should be continued only if the patient agrees to switch from subcutaneous to intravenous administration during pregnancy; subcutaneous administration allows higher peak concentrations that saturate FcRn receptors in the placenta during injection intervals, whereas intravenous administration maintains steady-state concentrations below the FcRn placental transfer threshold, reducing fetal exposure by approximately 60%.
• E) Dupilumab must be discontinued and replaced with cyclosporine for the duration of pregnancy; cyclosporine is the only FDA-approved systemic therapy for atopic dermatitis during pregnancy, with an established safety record in organ transplant recipients showing no increase in congenital anomalies; dupilumab has no established safety data in human pregnancy and is therefore contraindicated by default under precautionary prescribing principles.

12. [CASE 3 — QUESTION 4] Continuing with the same patient. She continued dupilumab throughout pregnancy and delivered a healthy infant at 39 weeks. The pediatrician is preparing the infant's vaccination schedule and asks the dermatologist whether any vaccines should be withheld or delayed due to maternal dupilumab exposure. Which pharmacological assessment of the neonatal vaccination risk is most accurate?

• A) The primary vaccination concern for infants born to mothers on dupilumab is the same as for any IgG-exposed infant; because dupilumab is an IgG4 antibody with lower FcRn-mediated placental transfer than IgG1 biologics, neonatal dupilumab concentrations — while detectable — are substantially lower than those achieved in infants born to mothers on IgG1 TNF inhibitors; dupilumab's mechanism (blocking IL-4Ralpha on epithelial cells and hematopoietic cells) does not suppress TNF-dependent granulomatous immunity or T-cell-mediated defense against live attenuated organisms in the same way that TNF inhibitors do; current guidance does not include a universal 6-month live vaccine deferral for infants born to mothers on dupilumab, though individualized assessment with the pediatrician is appropriate given limited neonatal safety data.
• B) All live vaccines should be withheld for 12 months in infants born to mothers on dupilumab because IgG4 antibodies have a longer serum half-life in neonates than IgG1 antibodies due to higher FcRn affinity; the extended neonatal IgG4 half-life means detectable dupilumab concentrations persist for up to 12 months, creating sustained IL-4Ralpha blockade that impairs the IL-4-dependent immunological priming required for live vaccine immunogenicity.
• C) Rotavirus vaccine (a live attenuated oral vaccine given at 2 months) is the only live vaccine of specific concern in this infant; dupilumab's IL-4Ralpha blockade impairs intestinal IgA responses to rotavirus specifically, as IgA class switching in the gut is entirely IL-4-dependent; all other live vaccines (MMR, varicella) can be given on the standard schedule because these are systemic vaccines that rely on IFN-gamma-mediated immunity unaffected by dupilumab.
• D) The infant should receive all vaccines on the standard schedule without modification; dupilumab does not cross the placenta because it is an IgG4 antibody, and IgG4 antibodies are excluded from FcRn-mediated placental transport; neonatal dupilumab concentrations are zero at birth regardless of maternal dose or gestational age at last administration.
• E) All live and inactivated vaccines should be withheld for the first 6 months of life; dupilumab's IL-4Ralpha blockade in the neonate suppresses both IL-4 and IL-13, eliminating the Th2 cytokine environment required for B-cell activation and antibody production to vaccine antigens; all vaccine immunogenicity is IL-4-dependent, and neonatal dupilumab exposure renders the infant temporarily unable to mount any antibody response to any vaccine until drug clearance is complete.

13. [CASE 4 — QUESTION 1] A 61-year-old man with rheumatoid arthritis has been on tofacitinib 5 mg twice daily for 22 months with excellent disease control. He has a history of type 2 diabetes and hypertension but no prior venous thromboembolism. He presents to the emergency department with acute onset dyspnea and pleuritic chest pain. CT pulmonary angiography confirms bilateral pulmonary emboli. Lower extremity duplex ultrasound identifies right femoral vein DVT. No other provoking factors are identified. Which immediate management and pharmacological explanation is most appropriate?

• A) Tofacitinib should be continued because the pulmonary emboli are provoked by the patient's diabetes-related endothelial dysfunction and hypertension-related venous stasis rather than by the drug; anticoagulation with apixaban should be initiated for the provoked VTE, and tofacitinib should be maintained to prevent RA disease flare during the acute illness; RA-related inflammation is itself a VTE risk factor, and discontinuing tofacitinib would expose the patient to a higher net VTE risk from uncontrolled inflammation.
• B) Tofacitinib should be dose-reduced from 5 mg twice daily to 5 mg once daily because the VTE black box warning applies specifically to the 10 mg twice daily dose used in the ORAL Surveillance trial; the 5 mg twice daily dose does not carry the same VTE risk, and dose reduction to 5 mg once daily achieves sufficient JAK1/JAK3 inhibition for RA control while eliminating the VTE-promoting JAK2 activity responsible for the thromboembolic complication.
• C) The VTE should be attributed to JAK1-mediated suppression of tissue plasminogen activator (tPA) transcription in endothelial cells; because tPA is the primary endogenous fibrinolytic enzyme, JAK1 inhibition by tofacitinib causes fibrinolytic failure and thrombus propagation rather than thrombus formation; the appropriate management is systemic thrombolysis to overcome the tPA deficiency, not drug discontinuation.
• D) Tofacitinib should be continued alongside indefinite anticoagulation; the FDA black box warning for VTE with JAK inhibitors recommends managing drug-associated VTE events with anticoagulation rather than drug discontinuation, as the RA inflammatory benefit of continued tofacitinib outweighs the VTE risk in patients who receive adequate anticoagulation therapy; indefinite DOAC therapy with concurrent tofacitinib is the standard labeled management recommendation.
• E) Tofacitinib should be discontinued because the FDA class-wide black box warning for JAK inhibitors includes venous thromboembolism — attributed mechanistically to JAK2-dependent thrombopoietin signaling alteration affecting platelet activation thresholds and potential STAT3-mediated suppression of anticoagulant gene transcription — and this patient's unprovoked bilateral pulmonary embolism with DVT occurring on tofacitinib, in a patient fitting the ORAL Surveillance high-risk profile (over 50 with cardiovascular risk factors), represents a drug-attributed serious adverse event; apixaban anticoagulation should be initiated immediately, and RA therapy should be transitioned to an alternative biologic class without the VTE risk profile, such as a TNF inhibitor or IL-6 receptor inhibitor.

14. [CASE 4 — QUESTION 2] Continuing with the same patient. Tofacitinib is discontinued and anticoagulation initiated. The rheumatologist selects abatacept for ongoing RA therapy. The patient asks how this drug works differently from the JAK inhibitor he was taking. Which explanation of abatacept's mechanism most accurately distinguishes it from tofacitinib?

• A) Abatacept is a monoclonal antibody that directly binds TNF-alpha in the extracellular space, neutralizing it before it can engage TNFR1 or TNFR2 on cell surfaces; unlike tofacitinib, which blocks intracellular JAK-STAT signaling downstream of multiple cytokine receptors, abatacept prevents a single upstream cytokine from initiating the entire downstream inflammatory cascade in RA synovium.
• B) Abatacept is a selective JAK2 inhibitor that provides more targeted immunosuppression than tofacitinib's JAK1/JAK3 inhibition; by inhibiting only JAK2, abatacept preserves gamma-c-chain cytokine signaling required for lymphocyte homeostasis while suppressing the JAK2-dependent erythropoietin and thrombopoietin pathways that were responsible for the patient's VTE through platelet hyperactivation.
• C) Abatacept is a fusion protein comprising the extracellular domain of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 — a co-inhibitory molecule normally expressed on activated T cells) fused to a modified IgG1 Fc region; it binds CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells with higher affinity than CD28, the co-stimulatory receptor on T cells; by occupying CD80/CD86 before CD28 can engage them, abatacept blocks the second signal required for full T-cell activation (the first signal being TCR-MHC engagement), rendering autoreactive T cells anergic rather than depeting them — a mechanism completely distinct from JAK-STAT intracellular kinase inhibition.
• D) Abatacept is a humanized anti-CD28 monoclonal antibody that directly blocks CD28 on T-cell surfaces, preventing CD28-CD80/86 co-stimulation; unlike tofacitinib, which suppresses cytokine signaling after T cells are already activated, abatacept prevents T-cell activation from occurring in the first place by directly antagonizing the CD28 receptor rather than its ligands CD80 and CD86 on antigen-presenting cells.
• E) Abatacept is a selective IL-2 receptor antagonist (anti-CD25 monoclonal antibody) that prevents IL-2 from binding its high-affinity receptor complex on activated T cells; this arrests T-cell proliferation at the G1/S checkpoint by blocking the JAK3-STAT5 signaling required for cell cycle progression — a mechanism that differs from tofacitinib by targeting the IL-2 receptor rather than the downstream JAK3 kinase, producing a more upstream blockade with a smaller off-target cytokine suppression footprint.

15. [CASE 4 — QUESTION 3] Continuing with the same patient. He recovers well and is stable on abatacept plus anticoagulation. His rheumatology fellow asks the attending about the ORAL Surveillance trial that underpins the JAK inhibitor black box warning, wanting to understand what the trial actually showed and why its findings led to class-wide labeling. Which description of the ORAL Surveillance trial and its regulatory consequences is most accurate?

• A) ORAL Surveillance was a randomized placebo-controlled trial that enrolled RA patients of all ages and risk profiles; tofacitinib at both 5 mg and 10 mg twice daily was compared to placebo; the trial found that tofacitinib increased the absolute risk of MACE by 3.5 events per 100 patient-years compared to placebo, providing the first proof that JAK inhibitor therapy causes cardiovascular harm through direct endothelial toxicity independent of underlying disease activity.
• B) ORAL Surveillance was a pharmacokinetic bioequivalence study that compared tofacitinib extended-release (XR) to immediate-release formulations; the study unexpectedly identified a VTE signal when extended-release tofacitinib was compared to TNF inhibitors as a reference arm; the class-wide warning was issued based solely on this pharmacokinetic study because no other JAK inhibitor data were available at the time of the FDA decision.
• C) ORAL Surveillance was a phase III efficacy trial that demonstrated tofacitinib's superiority to TNF inhibitors in ACR50 response rates (50% improvement in RA disease activity measures) in patients over 50 with cardiovascular risk factors; the safety signal was a secondary finding showing equivalent MACE rates but higher VTE rates; the VTE-only signal prompted the focused VTE component of the black box warning, while MACE and malignancy warnings were extrapolated from non-RA data.
• D) ORAL Surveillance was a post-marketing safety trial mandated by the FDA that randomized RA patients aged 50 years or older with at least one additional cardiovascular risk factor to tofacitinib (5 mg twice daily or 10 mg twice daily) versus a TNF inhibitor (adalimumab or etanercept); the active comparator design was critical — the trial showed that compared to established safe TNF inhibitors, tofacitinib was associated with statistically significant increases in MACE (nonfatal MI, nonfatal stroke, CV death), malignancy (particularly lung cancer and lymphoma), venous thromboembolism, and all-cause mortality; these findings led the FDA to issue class-wide black box warnings for all approved JAK inhibitors and to recommend preferential use of TNF inhibitors or other biologics in patients who fit the ORAL Surveillance high-risk profile.
• E) ORAL Surveillance enrolled both RA and non-RA patients (including those with inflammatory bowel disease and psoriasis) to establish a comprehensive JAK inhibitor safety database; the trial's primary endpoint was cancer incidence because JAK-STAT signaling regulates tumor suppressor gene transcription; the malignancy signal was the primary finding, while MACE and VTE were secondary outcomes; baricitinib was included in the trial as the second JAK inhibitor arm alongside tofacitinib, and their combined data formed the basis for the class-wide warning.

16. [CASE 4 — QUESTION 4] Continuing with the same patient. He has been stable on abatacept and anticoagulation for 2 years. His orthopedic surgeon schedules elective right knee replacement for RA-related joint destruction. The surgeon asks whether abatacept should be held before surgery and when it can be restarted. Which perioperative management approach is best supported by current biologic perioperative guidance?

• A) Abatacept should be continued through surgery without interruption because its mechanism — blocking CD80/CD86 rather than depleting T cells — means it does not produce the T-cell lymphopenia that increases surgical infection risk; only biologics that deplete lymphocytes (rituximab, alemtuzumab) require perioperative holding, while non-depleting co-stimulation blockers like abatacept can be maintained perioperatively without increased infection risk.
• B) Current ACR and EULAR guidelines recommend withholding biologic agents including abatacept for approximately one dosing interval (one half-life or one scheduled dose interval) before elective surgery to reduce the risk of surgical site infection and impaired wound healing; abatacept's half-life is approximately 13 to 14 days for intravenous and approximately 10 days for subcutaneous formulations; elective surgery should be scheduled so that it occurs at the end of the dosing interval when drug levels are at trough; abatacept can generally be restarted approximately 14 days postoperatively once wound healing is confirmed and no evidence of infection is present.
• C) Abatacept should be held for 6 months before any elective orthopedic surgery because abatacept's co-stimulation blockade mechanism prevents the T-cell activation required to mount an antimicrobial immune response against Staphylococcus aureus and Pseudomonas aeruginosa — the organisms that cause prosthetic joint infections; the 6-month drug holiday is required to restore full T-cell co-stimulation capacity before implanting a foreign body prosthesis.
• D) Abatacept has no perioperative restrictions because it specifically targets T-cell co-stimulation in lymph nodes — not in peripheral tissues or at the surgical wound; because abatacept's mechanism prevents antigen-driven T-cell activation in lymphoid organs rather than at the tissue level, it does not impair the innate immune wound healing response, neutrophil recruitment, or tissue macrophage function that are the primary defenses against surgical site infection.
• E) The decision to hold abatacept should be based on a serum abatacept drug level measurement; surgery should proceed only when the abatacept trough level falls below 1 mcg/mL, which requires a precise withholding period determined by the individual patient's pharmacokinetic parameters; empirical holding based on dosing intervals is pharmacologically inferior to drug-level-guided perioperative management and carries greater risk of either surgical infection (if residual drug is present) or RA flare (if drug is held unnecessarily long).

17. [CASE 5 — QUESTION 1] A 47-year-old woman has three co-existing immune-mediated conditions: moderate-to-severe plaque psoriasis (BSA 22%), active psoriatic arthritis (PsA) with involvement of multiple joints and enthesitis, and moderately active Crohn's disease (ileal) that has failed mesalamine. She has never received a biologic. Her multidisciplinary team — rheumatologist, gastroenterologist, and dermatologist — wants to identify a single biologic agent that provides meaningful benefit across all three conditions while avoiding the class-specific risks relevant to her combination. Which agent and mechanistic rationale best fits this clinical scenario?

• A) Risankizumab (selective IL-23 p19 inhibitor) is the most pharmacologically appropriate choice; by selectively blocking IL-23 — which drives Th17 expansion in psoriatic skin, synovial tissue, and intestinal mucosa — it addresses all three conditions; risankizumab is approved for plaque psoriasis and Crohn's disease, with clinical trial data supporting efficacy in psoriatic arthritis; it preserves the IL-12-Th1-IFN-gamma axis (which is suppressed by ustekinumab's dual p40 blockade), reducing the risk for intracellular infections; and it does not carry the IL-17 inhibitor class risk of IBD exacerbation, making it the optimal agent for this patient's combination of psoriasis, PsA, and Crohn's disease.
• B) Secukinumab (IL-17A inhibitor) is the most appropriate choice because IL-17A drives all three conditions simultaneously — psoriatic plaque keratinocyte proliferation, PsA synovial neutrophilic inflammation, and Crohn's disease ileal mucosal injury; blocking IL-17A with a single antibody provides the most mechanistically direct suppression across all three IL-17-driven inflammatory processes, and its monthly dosing schedule after initial loading maximizes patient adherence.
• C) Ustekinumab (anti-IL-12/23 p40) is the most appropriate choice because its dual blockade of IL-12 and IL-23 simultaneously suppresses both Th1-driven (Crohn's disease) and Th17-driven (psoriasis and PsA) inflammation; this comprehensive suppression of both major pro-inflammatory T-helper lineages is pharmacologically superior to selective IL-23p19 inhibitors, which leave IL-12-driven Th1 inflammation intact and therefore provide inferior Crohn's disease control.
• D) Tofacitinib (JAK1/JAK3 inhibitor) is the optimal oral treatment that could address all three conditions; it is approved for PsA and Crohn's disease and has substantial efficacy data in psoriasis; its oral administration avoids injection-related compliance issues; and the JAK inhibitor black box warning does not apply to patients under age 50 with no cardiovascular risk factors, making it safe for this 47-year-old patient without comorbidities.
• E) Infliximab (chimeric anti-TNF IgG1 monoclonal antibody) is the most appropriate first-choice biologic for this patient's triple combination; it is the only biologic with formal regulatory approval for all three conditions (plaque psoriasis, psoriatic arthritis, and Crohn's disease) in a single labeling document; its chimeric structure provides superior complement-fixation and ADCC-mediated synovial lining clearance compared to fully human TNF inhibitors, making it particularly effective for the musculoskeletal and intestinal components of this patient's disease.

18. [CASE 5 — QUESTION 2] Continuing with the same patient. She starts risankizumab with good response across all three conditions over 6 months. At month 6, her gastroenterologist orders routine post-initiation TB surveillance and her QuantiFERON-TB Gold Plus returns reactive. She has no prior TB treatment history, no respiratory symptoms, and a normal chest radiograph. She asks whether this means she has active TB and whether risankizumab must be permanently discontinued. Which response is most appropriate?

• A) A reactive IGRA 6 months into risankizumab therapy confirms active tuberculosis reactivation caused by the drug; risankizumab must be immediately discontinued, the patient must be placed in respiratory isolation, and full 4-drug anti-TB combination therapy (HRZE — isoniazid, rifampin, pyrazinamide, ethambutol) must be initiated; risankizumab is permanently contraindicated after TB reactivation.
• B) The reactive IGRA result is a false positive caused by risankizumab-induced immune dysregulation; IL-23 blockade causes polyclonal T-cell hyperactivation that produces non-specific IFN-gamma release in response to the QuantiFERON tuberculin antigens; the result should be dismissed and the patient continued on risankizumab without any anti-TB therapy.
• C) A reactive IGRA is expected in all patients on IL-23 inhibitors because these drugs upregulate IFN-gamma production by Th1 cells as a compensatory response to Th17 suppression; the elevated IFN-gamma directly causes a positive IGRA without any actual M. tuberculosis exposure; no clinical action is required and the test should not be repeated.
• D) The reactive IGRA confirms that the latent TB screening that should have been completed before risankizumab initiation was either not performed or that this represents seroconversion during therapy; the appropriate management is to add isoniazid prophylaxis to the current regimen, which should be continued for 9 months; risankizumab can be continued during isoniazid therapy because isoniazid does not affect risankizumab pharmacokinetics; the reactive IGRA does not indicate active TB in the absence of respiratory symptoms and with a normal chest radiograph.
• E) The reactive IGRA most likely represents latent TB infection (LTBI) that was either present before risankizumab initiation or acquired during therapy; a reactive IGRA with no respiratory symptoms and a normal chest radiograph is consistent with LTBI, not active TB; isoniazid prophylaxis should be initiated promptly (risankizumab can be continued during LTBI treatment as isoniazid does not affect biologic pharmacokinetics); this case highlights that TB screening should ideally be completed before any biologic initiation — if it was deferred due to clinical urgency, it should be performed as soon as possible after starting therapy, and any reactive result requires LTBI treatment regardless of when it is discovered relative to biologic initiation.

19. [CASE 5 — QUESTION 3] Continuing with the same patient. She has now completed 9 months of isoniazid LTBI treatment and remains on risankizumab for 18 months total. Her skin and joints remain well-controlled, but she develops a Crohn's disease flare with recurrent abdominal pain, increased stool frequency, and elevated fecal calprotectin. Colonoscopy confirms active ileocolonic inflammation. The gastroenterologist orders therapeutic drug monitoring (TDM — measurement of drug trough concentrations and anti-drug antibodies). Results show: risankizumab trough concentration 4.2 mcg/mL (adequate range greater than 2 mcg/mL), anti-risankizumab antibodies undetectable. Which interpretation and management approach is most appropriate?

• A) The adequate drug level with no anti-drug antibodies confirms that risankizumab is working correctly; the Crohn's flare is caused by a secondary infection (Clostridioides difficile or cytomegalovirus) in the setting of biologic immunosuppression, and the appropriate initial management is stool PCR for C. difficile and serum CMV PCR rather than any change to risankizumab dosing.
• B) The adequate trough concentration with undetectable anti-drug antibodies indicates pharmacodynamic failure rather than pharmacokinetic failure — the drug is present at adequate concentrations but is not producing sufficient biological response in the intestinal mucosa; this may reflect inadequate depth of IL-23 blockade at the tissue level, disease driven by an IL-23-independent pathway that has become dominant, or mucosal inflammation that has progressed beyond what this degree of IL-23 inhibition can control; appropriate options include risankizumab dose optimization (if a higher dose regimen is available), adding a conventional immunomodulator (azathioprine or 6-mercaptopurine), re-induction with a higher induction dose, or switching to a biologic with a different mechanism (vedolizumab, ustekinumab, or anti-TNF if not previously failed).
• C) The therapeutic drug level and absent ADA confirm complete target engagement; the Crohn's disease flare despite adequate risankizumab levels represents a paradoxical drug response in which IL-23 blockade increases Th1 activity through loss of competitive Th17 inhibition; the Th1-driven flare should be treated by switching to ustekinumab, which additionally blocks IL-12 and suppresses the unopposed Th1 response.
• D) The detectable risankizumab concentration confirms the drug is still active, but the Crohn's disease flare indicates that the drug has shifted from an anti-inflammatory to a pro-inflammatory role through an immunological class switch; continued risankizumab therapy in this patient will worsen IBD through a compensatory IL-17 surge caused by excessive IL-23 blockade; the drug must be permanently discontinued and replaced with vedolizumab (anti-integrin alpha4beta7) to prevent further intestinal inflammation.
• E) The therapeutic drug level combined with the Crohn's flare indicates that risankizumab must be immediately stopped because any degree of Crohn's disease activity while on adequate biologic therapy fulfills the definition of primary non-response; by regulatory definition, primary non-response requires discontinuation and switch to a non-cross-reactive biologic mechanism after a single flare on confirmed adequate drug exposure.

20. [CASE 5 — QUESTION 4] Continuing with the same patient. C. difficile and CMV testing are negative. The gastroenterologist recommends switching to vedolizumab for the Crohn's disease while the rheumatologist and dermatologist maintain risankizumab for the psoriasis and psoriatic arthritis. The patient asks how vedolizumab works and why it is safe to use simultaneously with risankizumab without excessive immunosuppression. Which explanation is most accurate?

• A) Vedolizumab is a humanized monoclonal antibody targeting MAdCAM-1 (mucosal addressin cell adhesion molecule 1) on gut endothelial cells; it prevents lymphocytes from recognizing the gut-specific vascular address that directs their homing to intestinal tissue; because MAdCAM-1 is expressed only on postcapillary venules in the intestinal lamina propria and not in skin or joints, vedolizumab provides gut-selective immunosuppression that does not affect the cutaneous and synovial T-cell populations targeted by risankizumab.
• B) Vedolizumab and risankizumab act on completely non-overlapping pathways and can be safely combined because vedolizumab is an IL-23 p19 inhibitor selectively expressed in intestinal tissue while risankizumab targets systemic IL-23; the combination of intestinal-specific and systemic IL-23 inhibition produces additive disease control without creating a combined immunosuppression footprint that exceeds either agent alone.
• C) Vedolizumab is an oral small-molecule S1P receptor modulator (like fingolimod) that sequesters lymphocytes in mesenteric lymph nodes specifically; because mesenteric lymph node sequestration does not remove lymphocytes from skin-draining lymph nodes or synovial tissue, vedolizumab's immunosuppressive effect is confined to the gastrointestinal tract, explaining its safety when combined with systemic biologics.
• D) Vedolizumab is a humanized monoclonal antibody targeting alpha4beta7 integrin expressed on gut-homing T lymphocytes and B lymphocytes; alpha4beta7 binds MAdCAM-1 (mucosal addressin cell adhesion molecule 1) on gut endothelial venules, directing lymphocyte trafficking specifically to the intestinal lamina propria; by blocking alpha4beta7, vedolizumab prevents gut-homing lymphocytes from extravasating into intestinal tissue without depleting them or affecting lymphocyte trafficking to skin, joints, lungs, or other non-intestinal sites; this gut-selective mechanism is why vedolizumab has a favorable systemic infection profile compared to non-selective biologics and why it can be combined with risankizumab for patients needing simultaneous gut and non-gut disease control.
• E) Vedolizumab targets alpha4beta7 integrin and provides complete immunosuppression of both gut and systemic lymphocyte populations because alpha4beta7 is expressed on all activated T cells during their initial activation phase regardless of tissue destination; all T cells transiently express alpha4beta7 before upregulating tissue-specific homing receptors, making vedolizumab a pan-T-cell trafficking inhibitor that achieves gut selectivity only at the low doses used clinically.

21. [CASE 6 — QUESTION 1] A 35-year-old woman with hereditary angioedema (HAE — recurrent attacks of subcutaneous and submucosal swelling due to C1-INH deficiency) who is 22 weeks pregnant presents to the emergency department with rapidly progressive tongue swelling, throat tightness, and voice changes consistent with laryngeal edema. She has no current HAE prophylaxis. She has a remote history of a non-HAE drug allergy to penicillin (rash only). Which treatment is most appropriate for this acute presentation?

• A) Intramuscular epinephrine 0.3 mg (1:1000) and intravenous diphenhydramine 50 mg should be administered immediately; laryngeal edema in pregnancy is most likely caused by IgE-mediated anaphylaxis triggered by an unidentified allergen; HAE laryngeal attacks are rare and life-threatening presentations are more commonly explained by anaphylaxis in the peripartum period; epinephrine is safe in pregnancy and is the correct first-line treatment.
• B) Systemic corticosteroids (methylprednisolone 125 mg IV) and antihistamine are first-line treatment; although HAE is bradykinin-mediated rather than histamine-mediated, high-dose corticosteroids suppress the contact system activation through non-genomic glucocorticoid receptor mechanisms and reduce bradykinin generation sufficiently to abort acute laryngeal attacks within 30–60 minutes; this approach is safe in pregnancy and avoids the fetal risks associated with C1-INH concentrate and plasma-derived products.
• C) Plasma-derived or recombinant C1-INH concentrate should be administered intravenously; C1-INH concentrate is considered the preferred acute treatment for severe HAE attacks including laryngeal edema in pregnancy — it restores the natural serpin inhibitor of the contact system and classical complement pathway, reducing bradykinin generation and rapidly terminating vascular permeability at the attack site; plasma-derived C1-INH products have been used safely in pregnancy and are considered first-line for life-threatening HAE attacks; airway monitoring and preparation for intubation or surgical airway should proceed simultaneously.
• D) Subcutaneous icatibant 30 mg is the preferred acute treatment because it is a bradykinin B2 receptor antagonist that rapidly terminates bradykinin-mediated vascular permeability and has the most convenient administration route; its rapid self-administration by the patient before arrival at the hospital is the key advantage over C1-INH concentrate, and because icatibant acts at the receptor rather than reducing bradykinin production, it is equally effective at a more advanced stage of attack when bradykinin has already been generated.
• E) Fresh frozen plasma (FFP) should be administered as the first-line treatment because it contains C1-INH along with all other complement and contact system proteins; FFP replenishes the entire contact system regulatory machinery and provides a pharmacological advantage over recombinant C1-INH concentrate, which provides only the single missing protein; FFP is the only blood product with regulatory approval for acute HAE in pregnancy.

22. [CASE 6 — QUESTION 2] Continuing with the same patient. She recovers fully from the laryngeal attack after C1-INH concentrate infusion. Her obstetrician and immunologist now discuss long-term HAE prophylaxis to prevent further attacks during the remainder of her pregnancy. The patient notes she was previously on lanadelumab 300 mg every 4 weeks before the pregnancy was known. Which statement regarding HAE prophylaxis management during pregnancy is most accurate?

• A) Plasma-derived C1-INH concentrate administered intravenously or subcutaneously every 3 to 4 days (or as needed based on attack frequency) is generally considered the preferred option for HAE prophylaxis during pregnancy based on its established safety record and mechanism of replacing the physiologically deficient protein; while data are limited for all HAE prophylactic agents in pregnancy, C1-INH concentrate has the most accumulated experience during gestation; lanadelumab's safety in pregnancy has not been established in controlled studies, and its use should be guided by individual risk-benefit assessment with specialist guidance; berotralstat (an oral plasma kallikrein inhibitor) is contraindicated in pregnancy based on animal reproductive toxicity data.
• B) Lanadelumab can be safely continued throughout pregnancy because as a fully human IgG1 monoclonal antibody it undergoes complete placental transfer via FcRn, providing simultaneous maternal and fetal plasma kallikrein inhibition; the resulting fetal kallikrein blockade prevents potentially harmful fetal bradykinin generation from the physiologically elevated kallikrein activity that occurs in the fetal circulation during the second and third trimesters.
• C) No HAE prophylaxis is required or recommended during pregnancy because physiological progesterone elevation suppresses kallikrein activity, and the estrogen-driven increase in C1-INH expression from the liver compensates for the genetic C1-INH deficiency during gestation; HAE attack frequency reliably decreases in all patients during pregnancy, making prophylaxis pharmacologically redundant.
• D) Tranexamic acid (an antifibrinolytic agent that inhibits plasminogen activation) is the recommended first-line prophylactic agent for HAE during pregnancy because it directly inhibits contact system activation through blockade of the factor XII (Hageman factor) autoactivation pathway; tranexamic acid is safe in pregnancy and is listed as the preferred HAE prophylactic agent in current obstetric anesthesia guidelines.
• E) Danazol (a synthetic androgen that upregulates hepatic C1-INH and C4 synthesis) is the preferred long-term HAE prophylactic agent during pregnancy because it addresses the root cause of the deficiency by stimulating endogenous C1-INH production; its androgenic effects are theoretical concerns only in the first trimester, and after 12 weeks of gestation, danazol is classified as a safe prophylactic agent in HAE pregnancies by major immunology society guidelines.

23. [CASE 6 — QUESTION 3] Continuing with the same patient. She delivers a healthy full-term infant without complications. She wishes to restart lanadelumab for HAE prophylaxis and asks whether she can breastfeed while on lanadelumab. She also notes that her HAE attacks have been more frequent in the postpartum period. Which counseling best addresses these concerns?

• A) Breastfeeding is absolutely contraindicated while on lanadelumab; lanadelumab is an IgG1 monoclonal antibody with the same structural properties as TNF inhibitors known to cause neonatal immunosuppression through breast milk transfer; infants who receive breast milk from mothers on lanadelumab develop systemic plasma kallikrein inhibition that suppresses the contact system required for neonatal hemostasis, causing a hemorrhagic diathesis in the first 6 months of life.
• B) Lanadelumab can be restarted immediately and breastfeeding is strongly encouraged; IgG1 antibodies present in breast milk are completely degraded by infant gastric acid before any gastrointestinal absorption occurs, making the oral bioavailability of IgG antibodies in breast milk effectively zero regardless of milk concentration; additionally, lanadelumab's kallikrein-inhibiting activity has no pharmacological effect on the infant because neonatal plasma kallikrein is a structurally distinct isoform that lanadelumab does not bind.
• C) Breastfeeding must be discontinued while the patient is on lanadelumab; the most appropriate postpartum HAE prophylaxis is berotralstat because, as an oral small molecule, it is not present in breast milk at detectable concentrations and can be used safely during lactation without any restriction on breastfeeding.
• D) While lanadelumab is detectable in human breast milk (as is the case for most IgG1 monoclonal antibodies), the clinical significance of this transfer to the breastfeeding infant is likely minimal because oral IgG antibodies are largely digested in the infant's gastrointestinal tract and are not bioavailable systemically at concentrations sufficient to produce pharmacological plasma kallikrein inhibition; current specialist guidance generally does not consider breastfeeding an absolute contraindication to lanadelumab, and the decision involves weighing the benefits of breastfeeding against the very limited data on infant exposure; the increase in postpartum HAE attack frequency is expected — the withdrawal of pregnancy's hormonal environment and the resumption of normal menstrual cycling increases contact system activation in many women with HAE, making effective prophylaxis particularly important in the early postpartum period.
• E) The patient should use formula feeding while on lanadelumab and should also be aware that lanadelumab is contraindicated in the postpartum period because postpartum estrogen withdrawal causes upregulation of bradykinin B2 receptor density on vascular endothelium; the increased receptor density means that even nanomolar concentrations of unbound bradykinin that escape lanadelumab's kallikrein blockade produce dramatically amplified vascular permeability, making lanadelumab ineffective and potentially dangerous during the first 3 months postpartum.

24. [CASE 6 — QUESTION 4] Continuing with the same patient. She is now 4 months postpartum, no longer breastfeeding, and is on lanadelumab 300 mg every 4 weeks with good attack control. She is scheduled for elective wisdom tooth extraction under local anesthesia in 2 weeks. Her dentist asks her HAE specialist whether any pre-procedural pharmacological preparation is required, noting that the patient has an upcoming lanadelumab dose 3 days after the dental procedure. Which recommendation for procedural HAE management is most appropriate?

• A) No pre-procedural preparation is required because lanadelumab's continuous plasma kallikrein inhibition provides complete protection against procedure-triggered HAE attacks; dental procedures including tooth extractions do not activate the contact system sufficiently to overcome therapeutic lanadelumab concentrations, and the patient's next dose 3 days after the procedure ensures sustained prophylactic coverage throughout the perioperative period.
• B) The wisdom tooth extraction should be postponed until the patient has completed 12 months of uninterrupted lanadelumab therapy; guideline evidence demonstrates that patients who have less than 12 months of established prophylaxis are at significantly higher risk for procedure-triggered HAE attacks; the contact activation from surgical trauma exceeds what any prophylactic agent can reliably suppress during the first year of therapy.
• C) Icatibant 30 mg subcutaneous injection should be given 1 hour before the procedure as pre-procedural prophylaxis; icatibant's bradykinin B2 receptor blockade provides a 6-hour window of protection against procedure-triggered bradykinin generation; this approach is superior to C1-INH concentrate because icatibant can be self-administered, acts within 30 minutes, and avoids the need for IV access required by C1-INH infusion.
• D) The lanadelumab dose should be advanced from 3 days post-procedure to 1 day before the procedure; advancing the scheduled dose creates maximum drug concentration at the time of surgical trauma; lanadelumab's peak concentration is achieved 7 to 14 days after injection, so administration 1 day before the procedure will result in peak drug levels on the day of highest attack risk (approximately day 8–15 post-procedure).
• E) Pre-procedural short-term prophylaxis with C1-INH concentrate administered intravenously 1 to 6 hours before the dental procedure is recommended because surgical and dental procedures — particularly those involving oropharyngeal manipulation, which can directly trigger facial and laryngeal HAE attacks — are recognized triggers for HAE; long-term prophylaxis with lanadelumab reduces background attack frequency but does not guarantee complete protection against procedure-triggered attacks; short-term prophylaxis with C1-INH concentrate immediately before the procedure provides an additional safety layer for the procedural period; the patient should also have icatibant available for self-administration if a breakthrough attack occurs despite prophylaxis.

25. [CASE 7 — QUESTION 1] A 58-year-old man who underwent renal transplantation 6 years ago for IgA nephropathy is on tacrolimus 3 mg twice daily and mycophenolate mofetil (MMF) 720 mg twice daily with stable graft function (creatinine 1.3 mg/dL). He now develops seropositive rheumatoid arthritis with active synovitis, elevated anti-CCP antibodies, and CRP of 22 mg/L. His rheumatologist considers adding a biologic. Which assessment of the pharmacological considerations unique to this patient's immunosuppression background is most accurate?

• A) A JAK inhibitor (baricitinib or upadacitinib) is the preferred biologic addition for this patient because JAK inhibitors work synergistically with tacrolimus through parallel calcineurin-NFAT blockade; both tacrolimus and JAK inhibitors converge on the IL-2 pathway — tacrolimus by blocking NFAT dephosphorylation and JAK inhibitors by blocking the IL-2 receptor JAK3 signaling — creating complementary dual-pathway IL-2 suppression that maximally prevents allograft rejection while simultaneously controlling RA.
• B) This patient requires careful consideration of layered immunosuppression risk; tacrolimus suppresses T-cell activation via calcineurin-NFAT inhibition (blocking IL-2 gene transcription), and MMF depletes guanosine nucleotides in proliferating lymphocytes via IMPDH inhibition; adding a JAK inhibitor would compound these mechanisms with broad cytokine signaling suppression, creating a risk of profound combined immunosuppression, opportunistic infections (including Pneumocystis jirovecii pneumonia, CMV reactivation, fungal infections), and malignancy that may be disproportionate to the RA indication; a TNF inhibitor, which has more established safety data in transplant patients, may be a more appropriate first biologic choice with lower additive immunosuppression risk.
• C) This patient cannot receive any biologic therapy because the combination of post-transplant immunosuppression and a biologic DMARD exceeds the safe total immunosuppression threshold established by transplant guidelines; the only RA therapy permissible in solid organ transplant recipients is hydroxychloroquine, which is the single DMARD with a safety record in post-transplant patients.
• D) Tacrolimus itself provides adequate RA disease control through its calcineurin inhibition mechanism; since calcineurin inhibitors block T-cell IL-2 production and T cells are the primary driver of RA synovitis, this patient's RA should already be well-controlled by his transplant immunosuppression; the synovitis and elevated CRP must therefore be attributed to calcineurin inhibitor-induced nephrotoxicity rather than active RA, and the management is tacrolimus dose adjustment rather than biologic addition.
• E) MMF should be discontinued before any biologic is added because MMF's IMPDH inhibition depletes the guanosine nucleotides required for TNF-alpha mRNA cap structure synthesis in macrophages; without guanosine nucleotides, TNF-alpha cannot be translated even if TNF gene transcription is intact, making TNF inhibitors pharmacologically redundant in patients on MMF; discontinuing MMF before biologic initiation restores TNF-alpha production and allows TNF inhibitors to have their therapeutic effect.

26. [CASE 7 — QUESTION 2] Continuing with the same patient. After careful multidisciplinary discussion, etanercept is started for RA. Four months later, his creatinine rises from 1.3 to 1.8 mg/dL, and a tacrolimus trough level returns at 18.2 ng/mL (target range 5–10 ng/mL for his transplant protocol at this timepoint). His transplant nephrologist immediately suspects a drug interaction and asks whether etanercept could be responsible for the elevated tacrolimus level. Which pharmacological assessment is most accurate?

• A) Etanercept is likely responsible for the elevated tacrolimus level because TNF-alpha normally upregulates CYP3A4 expression in the liver through NF-kB-mediated transcription of CYP3A4 gene promoter elements; by blocking TNF-alpha, etanercept reduces hepatic CYP3A4 expression, impairing tacrolimus metabolism and causing drug accumulation; the tacrolimus dose should be reduced by 30% empirically when starting any TNF inhibitor.
• B) The elevated tacrolimus level is caused by etanercept-mediated inhibition of P-glycoprotein (P-gp) in the intestinal epithelium; etanercept blocks TNF-alpha-dependent P-gp expression on enterocytes, increasing oral tacrolimus bioavailability; the interaction is specific to oral tacrolimus and would not occur with intravenous tacrolimus formulations.
• C) The elevated tacrolimus level confirms that etanercept activates the pregnane X receptor (PXR — a nuclear receptor that regulates CYP3A4 and other drug-metabolizing enzyme gene expression) in hepatocytes; PXR activation by etanercept's TNF-alpha blockade upregulates CYP3A4 paradoxically through a compensatory feedback mechanism, increasing tacrolimus hydroxylation and should cause lower, not higher, tacrolimus levels; because this patient's levels are elevated rather than reduced, etanercept cannot be the cause and another explanation must be sought.
• D) Biologic agents including etanercept do not inhibit CYP enzymes (CYP3A4, CYP2D6, etc.) or drug transporters (P-glycoprotein, OATP1B1) because they are large proteins metabolized by proteolytic degradation rather than by hepatic microsomal oxidation; tacrolimus is metabolized by CYP3A4 and is a P-glycoprotein substrate, but etanercept does not interact with these pathways; the elevated tacrolimus level must be attributed to another cause — most likely a recent change in diet (grapefruit, which inhibits CYP3A4), addition of a CYP3A4 inhibitor (azole antifungal, certain antibiotics, or calcium channel blockers), or altered gastrointestinal absorption from MMF-related mucosal changes; a thorough medication and dietary review is required.
• E) The elevated tacrolimus level is an expected consequence of the pharmacodynamic interaction between etanercept and tacrolimus; both drugs share a competitive binding site on the FK506-binding protein 12 (FKBP12) chaperone; by binding FKBP12, etanercept prevents tacrolimus from accessing its binding partner, paradoxically increasing free (unbound) tacrolimus concentrations in plasma; the tacrolimus assay measures total tacrolimus rather than free drug, and the elevated trough reflects FKBP12 competition rather than true tacrolimus accumulation.

27. [CASE 7 — QUESTION 3] Continuing with the same patient. The tacrolimus elevation was attributed to a brief course of fluconazole for oral candidiasis; fluconazole was discontinued and tacrolimus dose adjusted. Eight months into etanercept therapy, routine transplant surveillance CMV PCR returns at 3,400 IU/mL (threshold for pre-emptive treatment greater than 1,000 IU/mL in his transplant protocol). He is asymptomatic. Which management approach best integrates the immunopharmacological context of CMV reactivation in this patient?

• A) The CMV viremia is an expected consequence of calcineurin inhibitor therapy alone and is unrelated to etanercept; tacrolimus suppresses all T-cell responses including CMV-specific CD8 cytotoxic T-cell responses, and CMV reactivation is inevitable in any tacrolimus-treated transplant patient regardless of RA therapy; etanercept should be continued unchanged and valganciclovir initiated for CMV treatment per standard transplant protocol.
• B) Etanercept should be immediately and permanently discontinued because the CMV reactivation confirms that etanercept's TNF-alpha blockade has overwhelmed the patient's residual antiviral immunity; any further use of TNF inhibitors in this patient is permanently contraindicated because of the demonstrated inability to contain CMV; switching to hydroxychloroquine monotherapy for RA is the only safe option after CMV eradication.
• C) CMV reactivation in this patient reflects the cumulative immunosuppressive burden of tacrolimus (calcineurin inhibition suppressing CMV-specific T-cell responses), MMF (impairing lymphocyte proliferation including the expansion of CMV-specific CD8 cytotoxic T cells needed to contain the reactivating virus), and etanercept (TNF-alpha blockade impairing macrophage and NK-cell CMV containment); management should include prompt initiation of valganciclovir for pre-emptive antiviral treatment, and consideration of MMF dose reduction (the standard transplant immunosuppression adjustment for CMV — reducing antimetabolite burden while maintaining calcineurin inhibitor levels to protect the graft); temporary hold of etanercept may be considered while CMV is being treated, with restart decision based on viremia clearance and overall infection severity.
• D) CMV viremia at this level indicates active CMV end-organ disease requiring IV ganciclovir induction therapy and immediate referral for CMV retinitis evaluation; asymptomatic CMV viremia above 1,000 IU/mL is always accompanied by subclinical retinal infection in immunosuppressed patients, and ophthalmology evaluation should precede any antiviral treatment decision to determine the route of administration.
• E) The CMV viremia can be managed by increasing the tacrolimus dose to restore immunological tolerance to the CMV-infected graft cells; higher tacrolimus concentrations suppress the allo-reactive immune response that is simultaneously attacking CMV-infected graft cells and healthy transplanted kidney cells; this reduces inflammation, lowers the viral set point, and allows CMV to be cleared through residual innate immunity without antiviral therapy.

28. [CASE 7 — QUESTION 4] Continuing with the same patient. CMV viremia clears on valganciclovir and etanercept is restarted 6 weeks later. One year later, he presents with cervical lymphadenopathy and night sweats. Lymph node biopsy confirms EBV-positive diffuse large B-cell lymphoma (DLBCL) consistent with post-transplant lymphoproliferative disorder (PTLD — a spectrum of EBV-driven lymphoid proliferations occurring in the setting of post-transplant immunosuppression). Which pharmacological management principle is most critical in the initial management of PTLD?

• A) Immediate and substantial reduction or elimination of immunosuppression is the cornerstone of initial PTLD management; PTLD develops because the cumulative immunosuppressive burden — from tacrolimus, MMF, and etanercept in this patient — impairs EBV-specific CD8 cytotoxic T lymphocyte surveillance, allowing EBV-infected B cells to proliferate into a lymphomatous clone; reducing immunosuppression (typically by stopping or reducing MMF and reducing tacrolimus to the lowest dose that preserves graft function) allows recovery of EBV-specific T-cell responses that can drive spontaneous regression in lower-grade PTLD; for DLBCL-histology PTLD, reduction of immunosuppression is combined with rituximab (anti-CD20 monoclonal antibody, targeting the CD20-positive EBV-infected B cells), with chemotherapy reserved for rituximab-refractory disease; etanercept should be permanently discontinued given the contribution of TNF blockade to the impaired antiviral T-cell surveillance.
• B) Immunosuppression should be increased acutely because PTLD represents an allograft rejection variant in which the graft is being destroyed by EBV-infected B cells infiltrating renal parenchyma; intensifying tacrolimus and MMF prevents further B-cell infiltration while rituximab is given to deplete the infiltrating population; etanercept should be continued as it provides anti-inflammatory protection of the graft vasculature during B-cell depletion.
• C) PTLD is best managed with immediate switch from calcineurin inhibitor-based immunosuppression to mTOR inhibitor-based immunosuppression (sirolimus or everolimus); mTOR inhibitors have direct anti-proliferative activity against the B-cell clone through mTORC1 inhibition of lymphocyte protein synthesis; the transition from tacrolimus to sirolimus simultaneously addresses the underlying immunosuppression predisposition and provides direct anti-tumor activity against the PTLD clone.
• D) PTLD in this patient should be treated with empirical antiviral therapy (ganciclovir) before any reduction in immunosuppression; because EBV is the driver of B-cell lymphomagenesis in PTLD, eliminating EBV replication with ganciclovir will cause spontaneous DLBCL regression; immunosuppression reduction is deferred until EBV viremia is undetectable because reducing immunosuppression before viral control risks precipitating an immunoreconstitution inflammatory syndrome (IRIS) that could destroy both the tumor and the transplanted kidney.
• E) The PTLD should be managed with full-course RCHOP chemotherapy (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) as first-line therapy without any reduction in immunosuppression; maintaining full transplant immunosuppression prevents the alloimmune T-cell responses that accompany reduced calcineurin inhibitor dosing and that could simultaneously cause rejection during the DLBCL treatment course; the chemotherapy's immunosuppressive effects supersede the transplant medications, and simultaneous RCHOP plus tacrolimus/MMF is well-tolerated in published series.